Jemperli (dostarlimab) trial continues to show unprecedented ... - GSK
Jun 3, 2024 · GSK is advancing studies evaluating dostarlimab in patients with advanced/metastatic stages of dMMR/MSI-H colorectal cancer through its AZUR clinical trial …
About JEMPERLI (dostarlimab-gxly) - GSK
Aug 17, 2021 · GlaxoSmithKline (GSK) plc today announced the US Food and Drug Administration (FDA) approved a new indication for JEMPERLI (dostarlimab-gxly), a …
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mar 27, 2023 · GSK. European Commission approves GSK’s Jemperli (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer.
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US ... - GSK
Jul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin …
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the …
Dec 11, 2023 · GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary …
Positive RUBY phase III data show potential for Jemperli ... - GSK
Mar 16, 2024 · Part 1 of the RUBY phase III trial is investigating dostarlimab plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab compared to chemotherapy …
FDA grants accelerated approval to dostarlimab-gxly for dMMR …
On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair …
FDA expands endometrial cancer indication for dostarlimab-gxly
On August 1, 2024, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with...
FDA approves dostarlimab-gxly with chemotherapy for …
On July 31, 2023, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, …
EC Treatment Option for Certain Patients | JEMPERLI (dostarlimab …
Select your prescribed treatment to learn how JEMPERLI may help. I have been prescribed JEMPERLI with carboplatin and paclitaxel (CP) for my newly-diagnosed advanced or returned …